Molecular Health to Offer Early Access Program for SafetyMAP(TM)

Enrollment Now Open for Early Access Program (EAP) Set to Launch in November 2015

CAMBRIDGE, Mass., Oct. 5, 2015 (GLOBE NEWSWIRE) -- Molecular Health, a leader in cloud-based healthcare decision support technology to optimize the selection of therapies for improved patient outcomes, today announced that it will initiate an early access program (EAP) offering its SafetyMAP^TM software to pharmaceutical companies and clinical professionals involved in drug safety starting in November 2015.

Molecular Health recently entered into a commercial license to provide the U.S. Food and Drug Administration (FDA) with use of its SafetyMAP software, which the FDA considers a "mission critical" capability for assessing the importance of possible safety issues of drugs pre- and post-approval.

SafetyMAP is a comprehensive and dynamic analytical solution for the detection and molecular analysis of drug-induced adverse events for all marketed drugs and for predicting safety issues of new drug candidates. It is designed to help users further understand and discover relationships between scientific findings and diverse events and confirm relationships between drugs, toxicity mechanisms, patient susceptibility, and clinical effects. SafetyMAP provides an integrated approach not available in any single other tool to identify the safety interactions and adverse events related to specific drugs, drug classes, disease, and molecular targets and pathways.

Lutz Voelker, President and CEO of Molecular Health, said, "Ideal patient treatment selection is based upon the optimal efficacy of the therapy balanced against its optimal safety. Understanding and effectively managing treatment selection and the inherent safety profile of those treatments can alleviate considerable cost to the healthcare system. We are excited to offer an early access program for SafetyMAP to help support this complex issue and address drug development challenges. SafetyMAP, first available through the soon-to-launch EAP, is an instrumental value-add for pharmaceutical developers or clinical professionals making decisions in researching, developing and managing therapeutic treatments."